Neoadjuvant Chemotherapy Including Sorafenib in Women With Previously Untreated Primary Breast Cancer
The purpose of this study is to determine the efficacy and safety of sorafenib in the neoadjuvant setting in patients with primary breast cancer
Breast Cancer
DRUG: Nexavar (Sorafenib)
to establish the most feasible regimen of EC-P (P-EC) with sorafenib, Time of surgery
Safety of preoperative regimen, Treatment to Surgery|Determine clinical response rate, Time of surgery|Histopathological axillary nodal status after neoadjuvant therapy, Time of surgery|Correlate baseline and change in tumor and serum genetic, gene expression and proteomic patterns with clinical and pathological response, Baeline till time of surgery|pCR rate at surgery, Treatment ot Surgery
Epirubicin/Cyclophosphamide followed by Paclitaxel (EC/P) is a well tolerated regimen with high clinical activity. Histopathological complete remission after preoperative chemotherapy has a direct correlation with the disease-free and overall survival. The aim of combining a chemotherapy regime with sorafenib in the neoadjuvant setting is to increase the locoregional and systemic outcome of these patients